FAQ on HeartBeam Inc.'s CEO Appointment and 3D ECG Technology

Who has HeartBeam Inc. recently appointed to its Board of Directors?

HeartBeam Inc. has appointed its Chief Executive Officer, Robert Eno, to the Board of Directors, expanding the board from eight to nine members.

What experience does Robert Eno bring to HeartBeam Inc.?

Robert Eno brings over 30 years of medtech leadership experience, including launching disruptive technologies, to HeartBeam Inc.

What is HeartBeam Inc. preparing for with the appointment of Robert Eno to the Board?

The company is preparing for the commercial launch of its 3D ECG technology, pending FDA clearance of its 12-lead ECG synthesis software.

What makes HeartBeam’s 3D ECG technology unique?

HeartBeam’s technology is the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions, designed for use in portable devices outside medical facilities.

How many patents does HeartBeam Inc. hold?

HeartBeam Inc. holds 13 U.S. and 4 international-issued patents related to its technology enablement.

Where can I find more information about HeartBeam Inc.?

For more information, visit www.HeartBeam.com.

Where can investors find the latest news and updates about HeartBeam Inc.?

The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.

What is the significance of HeartBeam’s technology for cardiac care?

HeartBeam’s technology aims to transform cardiac care by enabling physicians to identify cardiac health trends and acute conditions outside of a medical facility, thus redefining the future of cardiac health management.